MARLBOROUGH, Mass., Nov. 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
On November 18, 2025, Kenneth Stein, M.D., senior vice president and global chief medical officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at Wolfe Research's 7th Annual Healthcare Conference. The session will begin at approximately 8:00 a.m. ET.
On December 2, 2025, Joe Fitzgerald, executive vice president and group president, Cardiology, Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, and Lauren Tengler, vice president, Investor Relations will participate in a 40-minute question-and-answer session with the host analyst at Citi's 2025 Global Healthcare Conference. The session will begin at approximately 9:00 a.m. ET.
A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
CONTACTS:
Emily Anderson
Media Relations
+1 (617) 515-2000
This email address is being protected from spambots. You need JavaScript enabled to view it.
Lauren Tengler
Investor Relations
+1 (508) 683-4479
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$96.88 |
| Daily Change: | 0.28 0.29 |
| Daily Volume: | 13,061,830 |
| Market Cap: | US$143.380B |
October 22, 2025 October 17, 2025 July 07, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load